在中级/低风险患有非清细胞细胞癌的患者中,基于免疫的组合:ARON-1研究结果
Francesco Massari1, Veronica Mollica2, Ray Manneh Kopp3
1Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna, Italy.
免疫检查点抑制剂/铁氨酸激酶抑制剂组合显示在非清细胞细胞癌 (nccRCC) 中具有优越的疗效. 布罗利祖马布/伦瓦提尼布在中等/低风险nccRCC患者中显示出显著的益处.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 细胞癌研究 细胞癌研究
背景情况:
- 非清晰细胞细胞癌 (nccRCC) 治疗缺乏免疫基组合的直接比较.
- 对于中等/低风险的nccRCC患者来说,还需要确定最佳的第一线疗法.
研究的目的:
- 在转移性nccRCC中评估一线免疫基组的现实疗效.
- 为了比较不同的免疫检查点抑制剂 (ICI) 加氨酸激酶抑制剂 (TKI) 方案.
主要方法:
- 在17个国家的56个中心对323名转移性nccRCC患者进行了回顾性多中心研究.
- 患者接受了第一线的pembrolizumab/lenvatinib,pembrolizumab/axitinib,nivolumab/cabozantinib或nivolumab/ipilimumab的治疗.
- 主要终点:整体存活率 (OS),无进展生存率 (PFS) 和整体反应率 (ORR).
主要成果:
- 平均生存期为31.1个月;2年生存率为58%.
- 总体应答率 (ORR) 为38%,PFS的中位数为13.0个月.
- ICI/TKI组合显著优于ICI双重剂,pembrolizumab/lenvatinib显示出显著的好处.
结论:
- ICI/TKI组合代表了中等/低风险nccRCC的最佳策略.
- 布罗利祖马布/伦瓦提尼布在这个患者群体中显示出明显的益处.
- 需要进一步的研究来验证这些现实世界的发现.
更多相关视频
15:04Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
15:24Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
相关概念视频
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistant Cancers
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
